Pazopanib based oral metronomic therapy for platinum resista
Treatment of patients with platinum-resistant/refractory epithelial ovarian cancer (EOC) is an unmet need. Oral metronomic therapy improves progression-free survival in patients with platinum-resistant/refractory ovarian cancer.

Seventy-five patients with platinum-resistant/refractory EOC were enrolled. Patients received oral etoposide (Arm A). Patients in Arm- B received Pazopanib in addition to etoposide and cyclophosphamide.

Quality of life (QoL) was evaluated using the EORTC questionnaire. Serum Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor (PDGF) were estimated at baseline, after the 3rd and 6th cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), toxicity, and QoL. Patients' characteristics were well matched.

--Median PFS was higher in arm B, 5.1 months compared to 3.4 months in arm A.

--Median OS has ‘not reached’ in Arm B compared to 11.2 months in arm A.

--Therapy was tolerated well; oral mucositis and fatigue being more in arm B.

--QoL assessment revealed modest improvement in ‘symptom scales’ in Arm B. Serum VEGF and PDGF levels decreased with therapy in both arms.

In summary, the addition of pazopanib to etoposide and cyclophosphamide could be a novel oral combination for metronomic therapy for platinum-resistant/refractory EOC.

Gynecologic Oncology